MedTech Breakthrough Recognizes Eisai, Biogen, and Medisafe for Alzheimer’s Disease Treatment Innovation

Renowned Global Awards Program Honors Exceptional Digital Health & Medical Technology Innovations

NUTLEY, N.J., May 27, 2025 – MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies, and products in the global digital health and medical technology market, announced that Eisai Inc., Biogen and Medisafe, have been awarded the “Best Care Coordination Platform” for the PATHWAYS tool in the 9^th annual MedTech Breakthrough Awards program.

PATHWAYS streamlines patient monitoring and enhances care coordination for patients receiving Alzheimer’s disease (AD) treatment. By tracking required dosing and monitoring protocols, this digital tool assists healthcare providers (HCPs), clinics and infusion centers to efficiently manage the care of patients who are undergoing treatment with FDA-approved monoclonal antibodies indicated for AD. PATHWAYS is a web-based platform that is currently being offered on a complimentary basis to healthcare providers treating patients with AD. Medisafe provides technical training, resources, and customer support to help with a smooth implementation.

The MedTech Breakthrough Awards program celebrates excellence and innovation in the health and medical technology industry, recognizing the companies, products, and solutions driving meaningful progress and improving patient care. Spanning a wide range of categories—including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices, Medical Data & Privacy, and beyond—the awards highlight the groundbreaking work transforming the healthcare landscape.

"We work every day to build an Alzheimer’s disease ecosystem that we hope will enhance how this progressive, devastating disease is diagnosed and treated. PATHWAYS is just one example of how Eisai and Biogen are working to simplify the treatment journey for people living with early Alzheimer's disease and their care teams," said Sarah Foster, Executive Director, Eisai Inc. "Eisai is proud to have collaborated with Biogen and Medisafe to make PATHWAYS available for the benefit of patients. We are honored to receive this recognition from MedTech Breakthrough, as it underscores Eisai’s commitment to our human health care mission and support of patients and healthcare professionals."

About Eisai Inc.

Eisai Inc. is a human health care (hhc) company dedicated to improving the lives of people affected by cancer, Alzheimer’s disease and other neurodegenerative conditions. Everything we do is guided by the simple principle that patients and their families come first, and we have a responsibility to listen to and learn from them.

Our hhc mission is the shared purpose that connects us to those we serve. It creates a network of powerful relationships that enable us to identify, understand and address unmet needs and healthcare disparities as we work towards achieving societal good.

Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. Our U.S. operations include discovery, research and development; manufacturing; global supply and logistics; and commercial activities.

To learn more, please visit us at https://us.eisai.com and connect with us on X and LinkedIn. For more information on our research, follow our dedicated neurology (LinkedIn and X) and oncology (LinkedIn and X) pages.